Edgewise Therapeutics Quarterly Income Statement
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
39.06-0.17 (-0.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edgewise Therapeutics revenue and earnings
Edgewise Therapeutics reported a net loss of $57.3 million, compared with a loss of $36.1 million a year earlier. Diluted earnings per share came in at -$0.53.
Summary generated from market data by MetaCap's automated system. Methodology
Edgewise Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 61.94M | 54.12M | 55.98M | 46.86M | 42.61M | 45.96M | 45.54M | 40.43M | 38.11M | 34.75M | 33.86M | 29.45M |
| Research & Development | 47.55M | 42.65M | 43.59M | 37.48M | 33.56M | 36.76M | 36.37M | 32.22M | 30.68M | 27.69M | 27.68M | 23.79M |
| Operating Income | -61.94M | -54.12M | -55.98M | -46.86M | -42.61M | -45.96M | -45.54M | -40.43M | -38.11M | -34.75M | -33.86M | -29.45M |
| Other Income (Expense) | 4.62M | 5.10M | 5.76M | 6.19M | 6.50M | 5.16M | 5.88M | 6.30M | 6.61M | 6.23M | 3.72M | 3.74M |
| Net Income | -57.33M | -49.01M | -50.22M | -40.67M | -36.12M | -40.80M | -39.66M | -34.13M | -31.50M | -28.52M | -30.14M | -25.71M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.46 | -0.41 |
| EPS (Diluted) | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.46 | -0.41 |
| Shares Outstanding (Basic) | 107.67M | 107.12M | — | 105.49M | 104.94M | 95.13M | — | 93.81M | 93.52M | 87.57M | — | 63.46M |
| Shares Outstanding (Diluted) | 107.67M | 107.12M | — | 105.49M | 104.94M | 95.13M | — | 93.81M | 93.52M | 87.57M | — | 63.46M |
| EBITDA | -61.44M | -53.58M | -55.45M | -46.36M | -42.11M | -45.45M | -44.96M | -39.93M | -37.61M | -34.28M | -33.38M | -29.05M |
This table shows 12 quarterly periods of Edgewise Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 10 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow EWTX's reporting calendar. What is a income statement?